>

Our Pipeline

We develop a broad portfolio of drug candidates that have the potential to meaningfully improve the lives of patients by directly addressing the causes and risk factors of neurodegenerative diseases.

Each of our programs strictly follows the principles of our R&D strategy: Selecting targets that are genetically linked to the disease, engineering our molecules to cross the blood-brain barrier, and guiding clinical development through the discovery and use of biomarkers.

Our Pipeline

Target Indication Drug Candidate
LRRK2 Parkinson's Early Clinical Early Clinical DNL201
LRRK2 Parkinson's Early Clinical Early Clinical DNL151
RIPK1 ALS, Alzheimer's, MS Early Clinical Early Clinical DNL747
Iduronate 2-sulfatase MPS II (Hunter Syndrome) IND-Enabling IND-Enabling DNL310 (ETV:IDS)
Alpha-Synuclein Parkinson's, DLB, MSA Drug Discovery Drug Discovery ATV:aSyn
Undisclosed Neurodegeneration Drug Discovery Drug Discovery LF1
TREM2 Alzheimer's Drug Discovery Drug Discovery ATV:TREM2
Tau Alzheimer's Drug Discovery Drug Discovery ATV:Tau
Undisclosed Neurodegeneration Drug Discovery Drug Discovery CH1
RIPK1 RA, Psoriasis IND-Enabling IND-Enabling DNL758
Drug Discovery IND-Enabling Early Clinical Late Clinical Approved
Patients